NIH GUIDE, Volume 21, Number 24, July 3, 1992

P.T. 34


  Grants Administration/Policy+ 

National Cancer Institute

The National Cancer Institute (NCI), with the concurrence of the

National Cancer Advisory Board, announces plans for the orderly phase

out and termination of its Outstanding Investigator Grant (OIG)

program.  All non-competing commitments for future year support made to

current grantees will continue to be honored as indicated on the

current Notice of Award.

This announcement makes permanent the moratorium on new (Type 1)

applications announced previously (NIH Guide Vol. 21, Number 14, April

10, 1992).  Any Type 1 OIG awards made in Fiscal 1993, based on

previously reviewed applications, will be for a 7-year project period

and will be non-renewable as an OIG as a condition of award.

Currently funded OIG investigators who already have submitted either

original or amended competing continuation applications (Type 2) for

the June 1, 1992 receipt date for consideration at the January 1993

National Cancer Advisory Board meeting will be considered to have

submitted a final competing application.  Competitive but unfunded Type

2 applications from that Board round will be kept in an eligible status

for an additional fiscal year.  Therefore, such applicants will not be

permitted to submit an amended competing continuation application for

the subsequent receipt date.  Where necessary to allow an orderly

transition to other support, OIG grantees may request administrative

extensions without additional funds for up to one year.

For all other current OIG awardees, a final round of Type 2 competing

continuation applications will be accepted for the June 1, 1993 receipt

date under the conditions specified below.  This will be the last

competing receipt date for the program prior to its termination.

1.  Only investigators whose current OIG awards will be in the -05 or

-06 year in Fiscal 1993, and who have not submitted a competing

application for the June 1992 receipt date, may submit a final,

non-renewable competing continuation application on June 1, 1993,

requesting up to seven years of additional support starting on the next

closest anniversary date of the current award.  The first competing

year proposed budget may not be increased more than 15 percent over the

last non-competing (-07) year actual award.  Applications requesting a

budgetary increase of greater than 15 percent above the -07 year level

will be accepted only with the prior approval of the NCI Executive

Committee.  Periods of time less than seven years may be requested for

this class of application.

2.  Any other investigator holding a non-competing Type 5 NCI OIG award

may, regardless of current non-competing years remaining, at his/her

own option, submit for the June 1, 1993 receipt date a final,

non-renewable competing continuation application requesting five

additional years of support, with the new budget period to commence

from the next closest immediate anniversary date of the current grant

period following selection for funding.  This submission will not place

at risk the current award, should the competing continuation

application fail to be funded.  The first competing year budget may not

request more than a 10 percent increment over the comparable

recommended budget level in the current award.  Future year requests

may not exceed current NIH award increment policies.

Although funds for these awards are provided for in the projected plans

of the NCI, given the uncertainties of budgets for future fiscal years,

it would be prudent for all applicants to submit individual research

project grant applications (e.g., R01 or P01) at the appropriate time

as alternative potential means of support should the competing

continuation OIG application not be funded.

Current OIG awardees are strongly encouraged to contact the NCI program

official identified on the Notice of Award to discuss future options

for the transition from support under the OIG to support under other

investigator-initiated grant mechanisms.


For additional information or for questions concerning this notice,


Mrs. Barbara S. Bynum

Director, Division of Extramural Activities

National Cancer Institute

Building 31, Room 10A03

Bethesda, MD  20892

Telephone:  (301) 496-5147

FAX:  (301) 402-0062


Return to 1992 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.